Filing Details

Accession Number:
0001127602-16-044956
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-03-03 19:59:31
Reporting Period:
2016-03-01
Filing Date:
2016-03-03
Accepted Time:
2016-03-03 19:59:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
884731 Ariad Pharmaceuticals Inc ARIA Biological Products, (No Disgnostic Substances) (2836) 223106987
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1461612 M Daniel Bollag C/O Ariad Pharmaceuticals, Inc.
26 Landsdowne Street
Cambridge MA 02139
Sr. Vp, Reg. Affairs & Quality No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-03-01 19,250 $0.00 160,713 No 4 M Direct
Common Stock Disposition 2016-03-03 9,625 $6.11 151,088 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Performance stock unit Disposition 2016-03-01 19,250 $0.00 19,250 $0.00
Common Stock Performance stock unit Acquisiton 2016-03-01 38,500 $0.00 38,500 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
19,250 No 4 M Direct
38,500 No 4 A Direct
Footnotes
  1. Shares were acquired upon vesting of performance stock units awarded on January 31, 2014.
  2. Represents shares sold to satisfy withholding tax requirements, pursuant to a Rule 10b5-1 trading plan.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.035 to $6.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
  4. Each performance stock unit represents a right to receive one share of ARIAD common stock.
  5. The performance stock units vest as to 50% of the award on 3/1/2016 and 50% of the award on 3/1/2017.